

Gene Therapy Cell Culture Media Market by Media Type (Serum Containing Media, Serum Free Media, Stem Cell Media, Specialty Media, Chemically Defined Media, Lysogeny Broth, Custom Media, and Others), Viral Vectors Type (Retroviruses, Lentiviruses, Adenoviruses, Adeno Associated Virus, Herpes Simplex Virus, Poxvirus, Vaccinia Virus, and Others), and End User (Biotechnology & Pharmaceutical Industry, Academic Institute, Research Laboratory, and Others): Global Opportunity Analysis and Industry Forecast, 2020–2027

<https://marketpublishers.com/r/G4EB2A653A09EN.html>

Date: January 2021

Pages: 262

Price: US\$ 6,168.00 (Single User License)

ID: G4EB2A653A09EN

Abstracts

The global gene therapy cell culture media market accounted for \$122.60 million in 2019, and is expected to reach \$278.96 million by 2027, registering a CAGR of 10.6% from 2020 to 2027.

Gene therapy cell culture media consists of important nutrients that provide ample energy to regulate healthy cell cycle. Moreover, it contains bovine serum, animal-derived nutrients, and growth factors like EGF, FGF, IGF, and PDGF. A surge in R&D activities worldwide are prime factor for the growth of the gene therapy cell culture media. Various pharmaceutical and biotechnology companies are heavily investing in R&D of gene therapy. Culture media are nutrient growth substances provided in laboratory and research settings for growth, proliferation, maintenance, and storage of microorganisms and other cell types such as stem cells, mammalian, and other cell lines. Different culture media are available in the market for various cell cultures to

survive and grow in their incubation environment.

Viral vectors include all viruses that can be used as vectors for the transfer of genes into a host cell. These vectors are further categorized into retroviruses, lentiviruses, adenoviruses, adeno-associated virus, herpes simplex virus, poxvirus, vaccinia virus, and others. Many gene therapy clinical trials have been conducted that make use of retroviruses or adenoviruses to deliver the desired gene. These viruses vary in regards with the mechanism of transferring the genes to those cells which they can recognize and then they infect, which leads to change in the cell's DNA permanently or temporarily.

The market growth is driven due to factors such as rise in R&D investments, and growth in awareness regarding gene therapy. However, dearth of skilled professionals, high costs associated with gene therapies, and ethical & scientific concerns associated with culture media hamper the market growth. Moreover, untapped potential of the emerging economies is expected to offer opportunities for gene therapy cell culture market growth during the forecast period.

The segment is divided into media type, viral vectors type, end user, and region. By media type is further divided into serum containing media, serum free media, stem cell media, specialty media, chemically defined media, lysogeny broth, custom media, and others. In addition, the viral vectors are divided into retroviruses, lentiviruses, adenoviruses, adeno associated virus, herpes simplex virus, poxvirus, vaccinia virus, and others. Further, by end user, the market is classified into biotechnology & pharmaceutical industry, academic institute, research laboratory, and others. By region, the gene therapy cell culture media market size is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

The gene therapy cell culture media market provides extensive competitive analysis and profiles of key market players, such as Fujifilm Holdings Corporation, HiMedia Laboratories Pvt., Ltd, Lonza Group Ltd, Sartorius AG, Thermo Fisher Scientific Inc., Merck KGaA, Danaher Corporation, Takara Holdings Inc., Novartis International AG, and Bio-Techne Corporation.

KEY BENEFITS FOR STAKEHOLDERS

This report entails a detailed quantitative analysis

of the current market trends from 2019 to 2027 to identify the prevailing opportunities.

The gene therapy cell culture media market size and estimations are based on comprehensive analysis of the key developments in the industry.

In-depth analysis based on region assists to understand the regional market and the strategic business planning.

The development strategies adopted by key manufacturers are enlisted to understand the competitive scenario of the market.

KEY MARKET SEGMENTS

By Media Type

Serum-containing Media

Serum-free Media

Stem Cell Media

Specialty Media

Chemically Defined Media

Lysogeny Broth

Custom Media

Others

By Viral Vectors Type

Retroviruses

Lentiviruses

Adenoviruses

Adeno-associated Virus

Herpes Simplex Virus

Poxvirus

Vaccinia Virus

Others

By End-User

Biotechnology & Pharmaceutical Industry

Academic Institute

Research Laboratory

Others

By Region

North America

U.S.

Canada

Mexico

Europe

Germany

France

UK

Italy

Spain

Rest of Europe

Asia-Pacific

China

Japan

India

Australia

South Korea

Rest of Asia-Pacific

LAMEA

Brazil

Saudi Arabia

South Africa

Rest of LAMEA

LIST OF KEY PLAYERS PROFILED IN THE REPORT

Fujifilm Holdings Corporation

HiMedia Laboratories Pvt., Ltd

Lonza Group Ltd

Sartorius AG (S

Thermo Fisher Scientific Inc.

Merck KGaA

Danaher Corporation

Takara Holdings Inc.

Novartis International AG

Bio-Techne Corporation

Contents

CHAPTER 1:INTRODUCTION

- 1.1.Report description
- 1.2.Key benefits for stakeholders
- 1.3.Key market segments
 - 1.3.1.List of key players profiled in the report
- 1.4.Research methodology
 - 1.4.1.Secondary research
 - 1.4.2.Primary research
 - 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

- 2.1.Key findings of the study
 - 2.1.1.CXO perspective

CHAPTER 3:MARKET OVERVIEW

- 3.1.Market definition and scope
- 3.2.Key findings
 - 3.2.1.Top investment pockets
 - 3.2.2.Top winning strategies
- 3.3.Top player positioning
- 3.4.Porter's five forces analysis
- 3.5.Market dynamics
 - 3.5.1.Drivers
 - 3.5.1.1.Rise in R&D investments
 - 3.5.1.2.Growth in awareness regarding gene therapy
 - 3.5.1.3.Increase in advancements associated gene therapy
 - 3.5.1.4.Increase in prevalence of cancer
 - 3.5.2.Restraints
 - 3.5.2.1.Dearth of skilled professionals
 - 3.5.2.2.High cost associated with gene therapies
 - 3.5.2.3.Ethical & scientific concerns associated with culture media
 - 3.5.3.Opportunity
 - 3.5.3.1.Untapped potential of the emerging economies
- 3.6.Impact Analysis of COVID-19 on Gene Therapy Cell Culture Media Market

CHAPTER 4: GENE THERAPY CELL CULTURE MEDIA MARKET, BY

MEDIA TYPE

4.1. Overview

4.1.1. Market size and forecast

4.2. Serum-containing media

4.2.1. Market size and forecast, by region

4.2.2. Market analysis by country

4.3. Serum-free media

4.3.1. Market size and forecast, by region

4.3.2. Market analysis by country

4.4. Stem cell media

4.4.1. Market size and forecast, by region

4.4.2. Market analysis by country

4.5. Specialty media

4.5.1. Market size and forecast, by region

4.5.2. Market analysis by country

4.6. Chemically defined media

4.6.1. Market size and forecast, by region

4.6.2. Market analysis by country

4.7. Lysogeny broth

4.7.1. Market size and forecast, by region

4.7.2. Market analysis by country

4.8. Custom media

4.8.1. Market size and forecast, by region

4.8.2. Market analysis by country

4.9. Other media

4.9.1. Market size and forecast, by region

4.9.2. Market analysis by country

CHAPTER 5: GENE THERAPY CELL CULTURE MEDIA MARKET, BY

VIRAL VECTORS TYPE

5.1. Overview

5.1.1. Market size and forecast

5.2. Retroviruses

5.2.1. Market size and forecast, by region

5.2.2. Market analysis by country

5.3.Lentiviruses

5.3.1.Market size and forecast, by region

5.3.2.Market analysis by country

5.4.Adenoviruses

5.4.1.Market size and forecast, by region

5.4.2.Market analysis by country

5.5.Adeno associated virus

5.5.1.Market size and forecast, by region

5.5.2.Market analysis by country

5.6.Herpes simplex virus

5.6.1.Market size and forecast, by region

5.6.2.Market analysis by country

5.7.Poxvirus

5.7.1.Market size and forecast, by region

5.7.2.Market analysis by country

5.8.Vaccinia virus

5.8.1.Market size and forecast, by region

5.8.2.Market analysis by country

5.9.Others

5.9.1.Market size and forecast, by region

5.9.2.Market analysis by country

CHAPTER 6:GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER

6.1.Overview

6.1.1.Market size and forecast

6.2.Pharmaceutical & biotechnology Industries

6.2.1.Market size and forecast, by region

6.2.2.Market analysis by country

6.3.Research Laboratories

6.3.1.Market size and forecast, by region

6.3.2.Market analysis by country

6.4.Academic Institutions

6.4.1.Market size and forecast, by region

6.4.2.Market analysis by country

6.5.Others

6.5.1.Market size and forecast, by region

6.5.2.Market analysis by country

CHAPTER 7: GENE THERAPY CELL CULTURE MEDIA MARKET, BY REGION

7.1. OVERVIEW

7.1.1. Market size and forecast

7.2. North America

7.2.1. Key market trends and opportunities

7.2.2. North America cell culture media market, by country

7.2.2.1. U.S. gene therapy cell culture media market, by media type

7.2.2.2. U.S. gene therapy cell culture media market, by viral vectors type

7.2.2.3. U.S. gene therapy cell culture media market, by end user

7.2.2.4. Canada gene therapy cell culture media market, by media type

- ##### 7.2.2.5. Canada gene therapy cell culture media market, by viral vectors type
- ##### 7.2.2.6. Canada gene therapy cell culture media market, by end user
- ##### 7.2.2.7. Mexico gene therapy cell culture media market, by media type
- ##### 7.2.2.8. Mexico gene therapy cell culture media market, by viral vectors type
- ##### 7.2.2.9. Mexico gene therapy cell culture media market, by end user
- #### 7.2.3. North America gene therapy cell culture media market, by media type
- #### 7.2.4. North America gene therapy cell culture media market, by viral vectors type
- #### 7.2.5. North America gene therapy cell culture media market, by end user

7.3. Europe

7.3.1. Key market trends and opportunities

7.3.2. Europe gene therapy cell culture media market, by country

7.3.2.1. Germany gene therapy cell culture media market, by media type

- ##### 7.3.2.2. Germany gene therapy cell culture media market, by viral vectors type
- ##### 7.3.2.3. Germany gene therapy cell culture media market, by end user
- ##### 7.3.2.4. France gene therapy cell culture media market, by media type
- ##### 7.3.2.5. France gene therapy cell culture media market, by viral vectors type
- ##### 7.3.2.6. France gene therapy cell culture media market, by end user
- ##### 7.3.2.7. UK gene therapy cell culture media market, by media type
- ##### 7.3.2.8. UK gene therapy cell culture media market, by viral vectors type
- ##### 7.3.2.9. UK gene therapy cell culture media market, by end user
- ##### 7.3.2.10. Italy gene therapy cell culture media market, by media type
- ##### 7.3.2.11. Italy gene therapy cell culture media market, by viral vectors type
- ##### 7.3.2.12. Italy gene therapy cell culture media market, by end user
- ##### 7.3.2.13. Spain gene therapy cell culture media market, by media type
- ##### 7.3.2.14. Spain gene therapy cell culture media market, by viral vectors type

- 7.3.2.15.Spain gene therapy cell culture media market, by end user
- 7.3.2.16.Rest of Europe gene therapy cell culture media market,
by media type
- 7.3.2.17.Rest of Europe gene therapy cell culture media market,
by viral vectors type
- 7.3.2.18.Rest of Europe gene therapy cell culture media market, by end user
- 7.3.3.Europe gene therapy cell culture media market, by media type
- 7.3.4.Europe gene therapy cell culture media market, by viral vectors type
- 7.3.5.Europe gene therapy cell culture media market, by end user
- 7.4.Asia-Pacific
 - 7.4.1.Key market trends and opportunities
 - 7.4.2.Asia-Pacific gene therapy cell culture media market, by country
 - 7.4.2.1.China gene therapy cell culture media market, by media type
 - 7.4.2.2.China gene therapy cell culture media market, by viral vectors type
 - 7.4.2.3.China gene therapy cell culture media market, by end user
 - 7.4.2.4.Japan gene therapy cell culture media market, by media type
 - 7.4.2.5.Japan gene therapy cell culture media market, by viral vectors type
 - 7.4.2.6.Japan gene therapy cell culture media market, by end user
 - 7.4.2.7.Australia gene therapy cell culture media market, by media type
 - 7.4.2.8.Australia gene therapy cell culture media market, by viral
vectors type
 - 7.4.2.9.Australia gene therapy cell culture media market, by end user
 - 7.4.2.10.India gene therapy cell culture media market, by media type
 - 7.4.2.11.India gene therapy cell culture media market, by viral vectors type
 - 7.4.2.12.India gene therapy cell culture media market, by end user
 - 7.4.2.13.South Korea gene therapy cell culture media market, by media type
 - 7.4.2.14.South Korea gene therapy cell culture media market, by viral
vectors type
 - 7.4.2.15.South Korea gene therapy cell culture media market, by end user
 - 7.4.2.16.Rest of Asia-Pacific gene therapy cell culture media market,
by media type
 - 7.4.2.17.Rest of Asia-Pacific gene therapy cell culture media market,
by viral vectors type
 - 7.4.2.18.Rest of Asia-Pacific gene therapy cell culture media market,
by end user
 - 7.4.3.Asia-Pacific gene therapy cell culture media market, by media type
 - 7.4.4.Asia-Pacific gene therapy cell culture media market, by
viral vectors type
 - 7.4.5.Asia-Pacific gene therapy cell culture media market, by end user

7.5.LAMEA

7.5.1.Key market trends and opportunities

7.5.2.LAMEA gene therapy cell culture media market, by country

7.5.2.1.Brazil gene therapy cell culture media market, by media type

7.5.2.2.Brazil gene therapy cell culture media market, by viral vectors type

7.5.3.Brazil gene therapy cell culture media market, by end user

7.5.3.1.Saudi Arabia gene therapy cell culture media market, by media type

7.5.3.2.Saudi Arabia gene therapy cell culture media market, by viral vectors type

7.5.4.Saudi Arabia gene therapy cell culture media market, by end user

7.5.4.1.South Africa gene therapy cell culture media market, by media type

7.5.4.2.South Africa gene therapy cell culture media market, by viral vectors type

7.5.5.South Africa gene therapy cell culture media market, by end user

7.5.5.1.Rest of LAMEA gene therapy cell culture media market, by media type

7.5.5.2.Rest of LAMEA gene therapy cell culture media market, by viral vectors type

7.5.6.REST OF LAMEA gene therapy cell culture media market, by end user

7.5.7.LAMEA gene therapy cell culture media market, by media type

7.5.8.LAMEA gene therapy cell culture media market, by viral vectors type

7.5.9.LAMEA gene therapy cell culture media market, by end user

CHAPTER 8:COMPANY PROFILES

8.1.BIO-TECHNE CORPORATION

8.1.1.Company overview

8.1.2.Company snapshot

8.1.3.Operating business segments

8.1.4.Operating product portfolio

8.1.5.Business performance

8.2.DANAHER CORPORATION (CYTIVA)

8.2.1.Company overview

8.2.2.Company snapshot

8.2.3.Operating business segments

8.2.4.Product portfolio

8.2.5.Business performance

8.3.FUJIFILM HOLDINGS CORPORATION (FUJIFILM IRVINE SCIENTIFIC)

- 8.3.1. Company overview
- 8.3.2. Company snapshot
- 8.3.3. Operating business segments
- 8.3.4. Product portfolio
- 8.3.5. Business performance
- 8.3.6. Key strategic moves and developments
- 8.4. HIMEDIA LABORATORIES
 - 8.4.1. Company overview
 - 8.4.2. Company snapshot
 - 8.4.3. Operating business segments
 - 8.4.4. Product portfolio
- 8.5. LONZA GROUP LTD
 - 8.5.1. Company overview
 - 8.5.2. Company snapshot
 - 8.5.3. Operating business segments
 - 8.5.4. Operating product portfolio
 - 8.5.5. Business performance
 - 8.5.6. Key strategic moves and developments
- 8.6. MERCK KGAA
 - 8.6.1. Company overview
 - 8.6.2. Company snapshot
 - 8.6.3. Operating business segments
 - 8.6.4. Product portfolio
 - 8.6.5. Business performance
 - 8.6.6. Key strategic moves and developments
- 8.7. NOVARTIS INTERNATIONAL AG
 - 8.7.1. Company overview
 - 8.7.2. Company snapshot
 - 8.7.3. Operating business segments
 - 8.7.4. Product portfolio
 - 8.7.5. Business performance
 - 8.7.6. Key strategic moves and developments
- 8.8. SARTORIUS AG
 - 8.8.1. Company overview
 - 8.8.2. Company snapshot
 - 8.8.3. Operating business segments
 - 8.8.4. Product portfolio
 - 8.8.5. Business performance
- 8.9. THERMO FISHER SCIENTIFIC, INC.

8.9.1.Company overview

8.9.2.Company snapshot

8.9.3.Operating business segments

8.9.4.Product portfolio

8.9.5.Business performance

8.9.6.Key strategic moves and developments

8.10.TAKARA HOLDINGS INC. (TAKARA BIO INC.)

8.10.1.Company overview

8.10.2.Company snapshot

8.10.3.Operating business segments

8.10.4.Product portfolio

8.10.5.Business performance

List Of Tables

LIST OF TABLES

TABLE 01.GENE THERPAY CELL CULTURE MEDIA MARKET BY MEDIA TYPE
2019-2027, (\$MILLION)

TABLE 02.GENE THERAPY CELL CULTURE MEDIA MARKET FOR SERUM
CONTAINING MEDIA, BY REGION
2019–2027(\$MILLION)

TABLE 03.GENE THERAPY CELL CULTURE MEDIA MARKET FOR SERUM FREE
MEDIA, BY REGION
2019–2027(\$MILLION)

TABLE 04.GENE THERAPY CELL CULTURE MEDIA MARKET FOR STEM CELL
MEDIA, BY REGION
2019–2027(\$MILLION)

TABLE 05.GENE THERAPY CELL CULTURE MEDIA MARKET FOR SPECIALTY
MEDIA, BY REGION
2019–2027(\$MILLION)

TABLE 06.GENE THERAPY CELL CULTURE MEDIA MARKET FOR CHEMICALLY
DEFINED MEDIA,
BY REGION 2019–2027(\$MILLION)

TABLE 07.GENE THERAPY CELL CULTURE MEDIA MARKET FOR LYSOGENY
BROTH, BY REGION
2019–2027(\$MILLION)

TABLE 08.GENE THERAPY CELL CULTURE MEDIA MARKET FOR CUSTOM
MEDIA, BY REGION
2019–2027(\$MILLION)

TABLE 09.GENE THERAPY CELL CULTURE MEDIA MARKET FOR OTHER MEDIA,
BY REGION
2019–2027(\$MILLION)

TABLE 10.GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR
TYPE 2019-2027, (\$MILLION)

TABLE 11.GENE THERAPY CELL CULTURE MEDIA MARKET FOR
RETROVIRUSES, BY REGION
2019–2027(\$MILLION)

TABLE 12.GENE THERAPY CELL CULTURE MEDIA MARKET FOR LENTIVIRUSES,
BY REGION
2019–2027(\$MILLION)

TABLE 13.GENE THERAPY CELL CULTURE MEDIA MARKET FOR

ADENOVIRUSES, BY REGION

2019–2027(\$MILLION)

TABLE 14.GENE THERAPY CELL CULTURE MEDIA MARKET FOR ADENO ASSOCIATED VIRUS, BY REGION

2019–2027(\$MILLION)

TABLE 15.GENE THERAPY CELL CULTURE MEDIA MARKET FOR HERPES SIMPLEX VIRUS, BY REGION

2019–2027(\$MILLION)

TABLE 16.GENE THERAPY CELL CULTURE MEDIA MARKET FOR POXVIRUS, BY REGION 2019–2027(\$MILLION)**TABLE 17.GENE THERAPY CELL CULTURE MEDIA MARKET FOR VACCINIA VIRUS, BY REGION**

2019–2027(\$MILLION)

TABLE 18.GENE THERAPY CELL CULTURE MEDIA MARKET FOR OTHERS, BY REGION 2019–2027(\$MILLION)**TABLE 19.GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER, 2019-2027 (\$MILLION)****TABLE 20.GENE THERAPY CELL CULTURE MEDIA MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY**

INDUSTRIES, BY REGION 2019–2027(\$MILLION)

TABLE 21.GENE THERAPY CELL CULTURE MEDIA MARKET FOR RESEARCH LABORATORIES, BY REGION

2019–2027 (\$MILLION)

TABLE 22.GENE THERAPY CELL CULTURE MEDIA MARKET FOR ACADEMIC INSTITUTIONS, BY REGION

2019–2027 (\$MILLION)

TABLE 23.GENE THERAPY CELL CULTURE MEDIA MARKET FOR OTHERS, BY REGION 2019–2027 (\$MILLION)**TABLE 24.GENE THERAPY CELL CULTURE MEDIA MARKET REVENUE, BY REGION, 2019–2027(\$MILLION)****TABLE 25.NORTH AMERICA GENE THERAPY CELL CULTURE MEDIA MARKET, BY COUNTRY,**

2019–2027(\$MILLION)

TABLE 26.U.S. GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE, 2019–2027(\$MILLION)**TABLE 27.U.S. GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE 2019-2027, (\$MILLION)****TABLE 28.U.S. GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER, 2019–2027(\$MILLION)**

TABLE 29.CANADA GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE, 2019–2027(\$MILLION)

TABLE 30.CANADA GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE

2019-2027, (\$MILLION)

TABLE 31.CANADA GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER, 2019–2027(\$MILLION)

TABLE 32.MEXICO GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE, 2019–2027(\$MILLION)

TABLE 33.MEXICO GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE

2019-2027, (\$MILLION)

TABLE 34.MEXICO GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER, 2019–2027(\$MILLION)

TABLE 35.NORTH AMERICA GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE,

2019–2027(\$MILLION)

TABLE 36.NORTH AMERICA GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE

2019-2027, (\$MILLION)

TABLE 37.NORTH AMERICA GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER,

2019–2027(\$MILLION)

TABLE 38.EUROPE GENE THERAPY CELL CULTURE MEDIA MARKET, BY COUNTRY, 2019–2027(\$MILLION)

TABLE 39.GERMANY GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE, 2019–2027(\$MILLION)

TABLE 40.GERMANY GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE

2019-2027, (\$MILLION)

TABLE 41.GERMANY GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER, 2019–2027(\$MILLION)

TABLE 42.FRANCE GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE, 2019–2027(\$MILLION)

TABLE 43.FRANCE GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE

2019-2027, (\$MILLION)

TABLE 44.FRANCE GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER, 2019–2027(\$MILLION)

TABLE 45.UK GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE, 2019–2027(\$MILLION)

TABLE 46.UK GENE THERAPY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE 2019-2027, (\$MILLION)

TABLE 47.UK GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER, 2019–2027(\$MILLION)

TABLE 48.ITALY GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE, 2019–2027(\$MILLION)

TABLE 49.ITALY GENE THERAPY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE 2019-2027, (\$MILLION)

TABLE 50.ITALY GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER, 2019–2027(\$MILLION)

TABLE 51.SPAIN GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE, 2019–2027(\$MILLION)

TABLE 52.SPAIN GENE THERAPY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE

2019-2027, (\$MILLION)

TABLE 53.SPAIN GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER, 2019–2027(\$MILLION)

TABLE 54.REST OF EUROPE GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE,

2019–2027(\$MILLION)

TABLE 55.REST OF EUROPE GENE THERAPY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE

2019-2027, (\$MILLION)

TABLE 56.REST OF EUROPE GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER,

2019–2027(\$MILLION)

TABLE 57.EUROPE GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE, 2019–2027(\$MILLION)

TABLE 58.EUROPE GENE THERAPY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE

2019-2027, (\$MILLION)

TABLE 59.EUROPE GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER, 2019–2027(\$MILLION)

TABLE 60.ASIA-PACIFIC GENE THERAPY CELL CULTURE MEDIA MARKET, BY COUNTRY, 2019–2027(\$MILLION)

TABLE 61.CHINA GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE, 2019–2027(\$MILLION)

TABLE 62.CHINA GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE

2019-2027, (\$MILLION)

TABLE 63.CHINA GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER, 2019–2027(\$MILLION)

TABLE 64.JAPAN GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE, 2019–2027(\$MILLION)

TABLE 65.JAPAN GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE

2019-2027, (\$MILLION)

TABLE 66.JAPAN GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER, 2019–2027(\$MILLION)

TABLE 67.AUSTRALIA GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE, 2019–2027(\$MILLION)

TABLE 68.AUSTRALIA GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE

2019-2027, (\$MILLION)

TABLE 69.AUSTRALIA GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER, 2019–2027(\$MILLION)

TABLE 70.INDIA GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE, 2019–2027(\$MILLION)

TABLE 71.INDIA GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE 2019-2027, (\$MILLION)

TABLE 72.INDIA GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER, 2019–2027(\$MILLION)

TABLE 73.SOUTH KOREA GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE,

2019–2027(\$MILLION)

TABLE 74.SOUTH KOREA GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE

2019-2027, (\$MILLION)

TABLE 75.SOUTH KOREA GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER, 2019–2027(\$MILLION)

TABLE 76.REST OF ASIA-PACIFIC GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE,

2019–2027(\$MILLION)

TABLE 77.REST OF ASIA-PACIFIC GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE

2019-2027, (\$MILLION)

TABLE 78.REST OF ASIA PACIFIC GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER, 2019–2027(\$MILLION)

TABLE 79.ASIA-PACIFIC GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE, 2019–2027(\$MILLION)

TABLE 80.ASIA PACIFIC GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE 2019-2027, (\$MILLION)

TABLE 81.ASIA- PACIFIC GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER, 2019–2027(\$MILLION)

TABLE 82.LAMEA GENE THERAPY CELL CULTURE MEDIA MARKET, BY COUNTRY, 2019–2027(\$MILLION)

TABLE 83.BRAZIL GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE, 2019–2027(\$MILLION)

TABLE 84.BRAZIL GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE 2019-2027, (\$MILLION)

TABLE 85.BRAZIL GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER, 2019–2027(\$MILLION)

TABLE 86.SAUDI ARABIA GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE, 2019–2027(\$MILLION)

TABLE 87.SAUDI ARABIA GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE 2019-2027, (\$MILLION)

TABLE 88.SAUDI ARABIA GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER, 2019–2027(\$MILLION)

TABLE 89.SOUTH AFRICA GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE, 2019–2027(\$MILLION)

TABLE 90.SOUTH AFRICA GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE 2019-2027, (\$MILLION)

TABLE 91.SOUTH AFRICA GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER, 2019–2027(\$MILLION)

TABLE 92.REST OF LAMEA GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE,

2019–2027(\$MILLION)

TABLE 93.REST OF LAMEA GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE

2019-2027, (\$MILLION)

TABLE 94.REST OF LAMEA GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER,

2019–2027(\$MILLION)20

TABLE 95.LAMEA GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE, 2019–2027(\$MILLION)

TABLE 96.ASIA PACIFIC GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE

2019-2027, (\$MILLION)

TABLE 97.LAMEA GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER, 2019–2027(\$MILLION)

TABLE 98.BIO-TECHNE: COMPANY SNAPSHOT

TABLE 99.OPERATING BUSINESS SEGMENT

TABLE 100.BIO-TECHNE: PRODUCT PORTFOLIO

TABLE 101.DANAHER: COMPANY SNAPSHOT

TABLE 102.DANAHER: OPERATING SEGMENT

TABLE 103.GE HEALTHCARE: PRODUCT PORTFOLIO

TABLE 104.FUJIFILM: COMPANY SNAPSHOT

TABLE 105.FUJIFILM: OPERATING SEGMENTS

TABLE 106.FUJIFILM: PRODUCT PORTFOLIO

TABLE 107.HIMEDIA: COMPANY SNAPSHOT

TABLE 108.HIMEDIA:OPERATING PRODUCT SEGMENT

TABLE 109.HIMEDIA: PRODUCT PORTFOLIO

TABLE 110.LONZA: COMPANY SNAPSHOT

TABLE 111.PRODUCT PORTFOLIO

TABLE 112.LONZA: PRODUCT PORTFOLIO

TABLE 113.SARTORIUS: KEY STRATEGIC MOVES AND DEVELOPMENTS

TABLE 114.MERCK: COMPANY SNAPSHOT

TABLE 115.MERCK: OPERATING SEGMENTS

TABLE 116.MERCK: PRODUCT PORTFOLIO

TABLE 117.SARTORIUS: KEY STRATEGIC MOVES AND DEVELOPMENTS

TABLE 118.NOVARTIS: COMPANY SNAPSHOT

TABLE 119.NOVARTIS: OPERATING SEGMENTS

TABLE 120.NOVARTIS: PRODUCT PORTFOLIO

TABLE 121.SARTORIUS: COMPANY SNAPSHOT

TABLE 122.SARTORIUS: OPERATING BUSINESS SEGMENTS

TABLE 123.SARTORIUS: PRODUCT PORTFOLIO

TABLE 124.THERMO FISHER: COMPANY SNAPSHOT

TABLE 125.THERMO FISHER.: OPERATING SEGMENTS

TABLE 126.THERMO FISHER.: PRODUCT PORTFOLIO

TABLE 127.THERMO FISHER SCIENTIFIC : KEY STRATEGIC MOVES AND
DEVELOPMENTS

TABLE 128.TAKARA GROUP: COMPANY SNAPSHOT

TABLE 129.TAKARA GROUP: OPERATING SEGMENTS

TABLE 130.TAKARA GROUP: PRODUCT PORTFOLIO

List Of Figures

LIST OF FIGURES

FIGURE 01.GENE THERAPY CELL CULTURE MEDIA MARKETSEGMENTATION

FIGURE 02.TOP INVESTMENT POCKETS

FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2018-2020*

FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018-2020*

FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2018-2020*

FIGURE 06.MODERATE BARGAINING POWER OF BUYERS

FIGURE 07.LOW BARGAINING POWER OF SUPPLIERS

FIGURE 08.MODERATE THREAT OF NEW ENTRANTS

FIGURE 09.LOW THREAT OF SUBSTITUTION

FIGURE 10.MODERATE COMPETITIVE RIVALRY

FIGURE 11.DRIVERS, RESTRAINTS, AND OPPORTUNITIES

FIGURE 12.GENE THERAPY PIPELINE VOLUME, PRECLINICAL THROUGH PRE-REGISTRATION PHASE, 1995–2018

FIGURE 13.COMPARATIVE SHARE ANALYSIS OF GENE THERAPY CELL CULTURE MEDIA MARKET FOR

SERUM CONTAINING MEDIA, BY COUNTRY, 2019 & 2027 (%)

FIGURE 14.COMPARATIVE SHARE ANALYSIS OF GENE THERAPY CELL CULTURE MEDIA MARKET FOR

SERUM FREE MEDIA, BY COUNTRY, 2019 & 2027 (%)

FIGURE 15.COMPARATIVE SHARE ANALYSIS OF GENE THERAPY CELL CULTURE MEDIA MARKET FOR

STEM CELL MEDIA, BY COUNTRY, 2019 & 2027 (%)

FIGURE 16.COMPARATIVE SHARE ANALYSIS OF GENE THERAPY CELL CULTURE MEDIA MARKET FOR

SPECIALTY MEDIA, BY COUNTRY, 2019 & 2027 (%)

FIGURE 17.COMPARATIVE SHARE ANALYSIS OF GENE THERAPY CELL CULTURE MEDIA MARKET FOR

CHEMICALLY DEFINED MEDIA, BY COUNTRY, 2019 & 2027 (%)

FIGURE 18.COMPARATIVE SHARE ANALYSIS OF GENE THERAPY CELL CULTURE MEDIA MARKET FOR

LYSOGENY BROTH, BY COUNTRY, 2019 & 2027 (%)

FIGURE 19.COMPARATIVE SHARE ANALYSIS OF GENE THERAPY CELL CULTURE MEDIA MARKET FOR

CUSTOM MEDIA, BY COUNTRY, 2019 & 2027 (%)

FIGURE 20.COMPARATIVE SHARE ANALYSIS OF GENE THERAPY CELL

CULTURE MEDIA MARKET FOR

OTHER MEDIA, BY COUNTRY, 2019 & 2027 (%)

FIGURE 21.COMPARATIVE SHARE ANALYSIS OF GENE THERAPY CELL
CULTURE MEDIA MARKET FOR

RETROVIRUSES, BY COUNTRY, 2019 & 2027 (%)

FIGURE 22.COMPARATIVE SHARE ANALYSIS OF GENE THERAPY CELL
CULTURE MEDIA MARKET FOR

LENTIVIRUSES, BY COUNTRY, 2019 & 2027 (%)

FIGURE 23.COMPARATIVE SHARE ANALYSIS OF GENE THERAPY CELL
CULTURE MEDIA MARKET FOR

ADENOVIRUSES, BY COUNTRY, 2019 & 2027 (%)

FIGURE 24.COMPARATIVE SHARE ANALYSIS OF GENE THERAPY CELL
CULTURE MEDIA MARKET FOR

ADENO ASSOCIATED VIRUS, BY COUNTRY, 2019 & 2027 (%)

FIGURE 25.COMPARATIVE SHARE ANALYSIS OF GENE THERAPY CELL
CULTURE MEDIA MARKET FOR

HERPES SIMPLEX VIRUS, BY COUNTRY, 2019 & 2027 (%)

FIGURE 26.COMPARATIVE SHARE ANALYSIS OF GENE THERAPY CELL
CULTURE MEDIA MARKET FOR

POXVIRUS, BY COUNTRY, 2019 & 2027 (%)

FIGURE 27.COMPARATIVE SHARE ANALYSIS OF GENE THERAPY CELL
CULTURE MEDIA MARKET FOR

VACCINIA VIRUS, BY COUNTRY, 2019 & 2027 (%)

FIGURE 28.COMPARATIVE SHARE ANALYSIS OF GENE THERAPY CELL
CULTURE MEDIA MARKET FOR

OTHERS, BY COUNTRY, 2019 & 2027 (%)

FIGURE 29.COMPARATIVE SHARE ANALYSIS OF GENE THERAPY CELL
CULTURE MEDIA MARKET FOR

PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRIES, BY COUNTRY, 2019 & 2027
(%)

FIGURE 30.COMPARATIVE SHARE ANALYSIS OF GENE THERAPY CELL
CULTURE MEDIA MARKET FOR

RESEARCH LABORATORIES, BY COUNTRY, 2019 & 2027 (%)

FIGURE 31.COMPARATIVE SHARE ANALYSIS OF CELL CULTURE MARKET FOR
ACADEMIC INSTITUTIONS,

BY COUNTRY, 2019 & 2027 (%)

FIGURE 32.COMPARATIVE SHARE ANALYSIS OF GENE THERAPY CELL
CULTURE MEDIA MARKET FOR

OTHERS, BY COUNTRY, 2019 & 2027 (%)

FIGURE 33.BIO-TECHNE: NET SALES, 2017–2019 (\$MILLION)
FIGURE 34.BIO-TECHNE: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 35.BIO-TECHNE: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 36.DANAHER: NET SALES, 2017–2019 (\$MILLION)
FIGURE 37.DANAHER: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 38.DANAHER: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 39.FUJIFILM: NET SALES, 2018–2020 (\$MILLION)
FIGURE 40.FUJIFILM: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 41.LONZA: NET SALES, 2017–2019 (\$MILLION)
FIGURE 42.LONZA: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 43.MERCK: NET SALES, 2017–2019 (\$MILLION)
FIGURE 44.MERCK: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 45.MERCK: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 46.NOVARTIS: NET SALES, 2017–2019 (\$MILLION)
FIGURE 47.NOVARTIS: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 48.NOVARTIS: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 49.SARTORIUS: NET SALES, 2017–2019 (\$MILLION)
FIGURE 50.SARTORIUS: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 51.SARTORIUS: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 52.THERMO FISHER: NET SALES, 2017–2019 (\$MILLION)
FIGURE 53.THERMO FISHER: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 54.THERMO FISHER: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 55.TAKARA GROUP: NET SALES, 2017–2019 (\$MILLION)
FIGURE 56.TAKARA GROUP: REVENUE SHARE, BY SEGMENT, 2019 (%)

I would like to order

Product name: Gene Therapy Cell Culture Media Market by Media Type (Serum Containing Media, Serum Free Media, Stem Cell Media, Specialty Media, Chemically Defined Media, Lysogeny Broth, Custom Media, and Others), Viral Vectors Type (Retroviruses, Lentiviruses, Adenoviruses, Adeno Associated Virus, Herpes Simplex Virus, Poxvirus, Vaccinia Virus, and Others), and End User (Biotechnology & Pharmaceutical Industry, Academic Institute, Research Laboratory, and Others): Global Opportunity Analysis and Industry Forecast, 2020–2027

Product link: <https://marketpublishers.com/r/G4EB2A653A09EN.html>

Price: US\$ 6,168.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G4EB2A653A09EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970